Restoration of dopamine transporter density in the striatum of fetal ventral mesencephalon-grafted, but not sham-grafted, MPTP-treated parkinsonian monkeys.

[1]  R. Roth,et al.  Early gestational mesencephalon grafts, but not later gestational mesencephalon, cerebellum or sham grafts, increase dopamine in caudate nucleus of MPTP-treated monkeys , 1996, Neuroscience.

[2]  L. Olson,et al.  Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo , 1995, Nature.

[3]  R. Vandlen,et al.  Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain , 1995, Nature.

[4]  J. Naegele,et al.  Long-Term Behavioral Recovery in Parkinsonian Rats by an HSV Vector Expressing Tyrosine Hydroxylase , 1994, Science.

[5]  John L. Hudson,et al.  Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo , 1994, Neuroscience Letters.

[6]  T. Collier,et al.  Neural graft augmentation through co-grafting: Implantation of cells as sources of survival and growth factors , 1994, Progress in Neurobiology.

[7]  M. Sanghera,et al.  Low dopamine transporter mRNA levels in midbrain regions containing calbindin. , 1994, Neuroreport.

[8]  D. E. Redmond,et al.  Peripheral nerve-dopamine neuron co-grafts in mptp-treated monkeys: Augmentation of tyrosine hydroxylase-positive fiber staining and dopamine content in host systems , 1994, Neuroscience.

[9]  R. Roth,et al.  Novel Radioligands for the Dopamine Transporter Demonstrate the Presence of Intrastriatal Nigral Grafts in the MPTP-Treated Monkey: Correlation with Improved Behavioral Function , 1994, Experimental Neurology.

[10]  R. Roth,et al.  Can Graft-Derived Neurotrophic Activity Be Used to Direct Axonal Outgrowth of Grafted Dopamine Neurons for Circuit Reconstruction in Primates? , 1993, Experimental Neurology.

[11]  M. Sofroniew,et al.  Trophism, Transplantation, and Animal Models of Parkinson's Disease , 1993, Experimental Neurology.

[12]  Y. Agid,et al.  Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP? , 1993, Neuroscience.

[13]  D. Spencer,et al.  Neural Transplantation for Neurodegenerative Diseases: Past, Present, and Future a , 1993, Annals of the New York Academy of Sciences.

[14]  R. Roth,et al.  Fetal Dopamine Cell Survival after Transplantation Is Dramatically Improved at a Critical Donor Gestational Age in Nonhuman Primates , 1993, Experimental Neurology.

[15]  C D Marsden,et al.  Alterations in striatal and extrastriatal D‐1 and D‐2 dopamine receptors in the MPTP‐treated common marmoset: An autoradiographic study , 1993, Synapse.

[16]  A. Björklund.  Better cells for brain repair , 1993, Nature.

[17]  A. Björklund,et al.  Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) , 1992, The New England journal of medicine.

[18]  Scott T. Grafton,et al.  Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. , 1992, The New England journal of medicine.

[19]  D. Spencer,et al.  Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. , 1992, The New England journal of medicine.

[20]  A. Björklund.  Dopaminergic transplants in experimental parkinsonism: cellular mechanisms of graft-induced functional recovery , 1992, Current Opinion in Neurobiology.

[21]  M. Kuhar,et al.  Isopropyl and phenyl esters of 3 beta-(4-substituted phenyl)tropan-2 beta-carboxylic acids. Potent and selective compounds for the dopamine transporter. , 1992, Journal of medicinal chemistry.

[22]  O. Hornykiewicz,et al.  Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey , 1991, Neuroscience.

[23]  O. Lindvall.  Prospects of transplantation in human neurodegenerative diseases , 1991, Trends in Neurosciences.

[24]  A. Björklund.  Neural transplantation — an experimental tool with clinical possibilities , 1991, Trends in Neurosciences.

[25]  R. Artymyshyn,et al.  The use of 3H standards in 125I autoradiography , 1990, Journal of Neuroscience Methods.

[26]  R. Roth,et al.  MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys , 1990, Brain Research.

[27]  D. Jacobowitz,et al.  The effect of fetal mesencephalon implants on primate MPTP-induced parkinsonism. Histochemical and behavioral studies. , 1990, Journal of neurosurgery.

[28]  R. Roth,et al.  Symptomatic and asymptomatic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated primates: Biochemical changes in striatal regions , 1989, Neuroscience.

[29]  J. Kordower,et al.  Adrenal medullary autografts into the basal ganglia of Cebus monkeys: Injury-induced regeneration , 1988, Experimental Neurology.

[30]  R. Roth,et al.  Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF , 1987, Brain Research.

[31]  Richard F. Martin,et al.  Primate neostriatal neurons containing tyrosine hydroxylase: Immunohistochemical evidence , 1987, Neuroscience Letters.

[32]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[33]  C. Ricordi.  Methods in cell transplantation , 1995 .

[34]  R. Roth,et al.  Sham surgery does not ameliorate MPTP-induced behavioral deficits in monkeys. , 1995, Cell transplantation.

[35]  R. Roth,et al.  Behavioral Effects of MPTP Administration in the Vervet Monkey , 1994 .

[36]  W. Freed.  Substantia nigra grafts and Parkinson's disease: from animal experiments to human therapeutic trials. , 1991, Restorative neurology and neuroscience.

[37]  D. Jacobowitz,et al.  Fetal nondopaminergic neural implants in parkinsonian primates. Histochemical and behavioral studies. , 1991, Journal of neurosurgery.

[38]  E. Oldfield,et al.  Behavioral recovery from MPTP-induced parkinsonism in monkeys after intracerebral tissue implants is not related to CSF concentrations of dopamine metabolites. , 1990, Progress in brain research.

[39]  A. Björklund,et al.  Can human fetal dopamine neuron grafts provide a therapy for Parkinson's disease? , 1988, Progress in brain research.

[40]  D. Jacobowitz,et al.  Transient behavioral recovery in hemiparkinsonian primates after adrenal medullary allografts. , 1988, Progress in brain research.

[41]  R. Roth,et al.  Fetal dopamine neural grafts: extended reversal of methylphenyltetrahydropyridine-induced parkinsonism in monkeys. , 1988, Progress in brain research.

[42]  A. Hendrickx,et al.  Prenatal growth in the cynomolgus and rhesus macaque (Macaca fascicularis and Macaca mulatta): A comparison by ultrasonography , 1988, American journal of primatology.

[43]  D. Jacobowitz,et al.  N-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP) causes destruction of the nigrostriatal but not the mesolimbic dopamine system in the monkey. , 1984, Psychopharmacology bulletin.